Imaging Technology
MAY 17, 2024
milla1cf Fri, 05/17/2024 - 18:43 May 17, 2024 — Registration opens today for the American Society for Radiation Oncology's ( ASTRO ) 66th Annual Meeting, which will be held at the Walter E. September 29 – October 2, 2024. Washington Convention Center in Washington, D.C.,
Imaging Technology
APRIL 5, 2024
milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
MARCH 7, 2024
year over year, according to the newly published IMV 2024 PET Market Summary Report. In terms of 2023 spending, the average radiopharmaceutical expenditure per fixed PET site is estimated to be $517,000. IMV's 2024 PET Market Summary Report explores market trends in U.S. Davin Korstjens.
Imaging Technology
APRIL 2, 2024
milla1cf Tue, 04/02/2024 - 18:51 April 2, 2024 — Less than three months after signing an agreement to acquire MIM Software Inc. , GE HealthCare Technologies Inc. Radiation therapy – a type of treatment given alone or in combination with surgery and/or chemotherapy – is administered to nearly two-thirds of all cancer patients.i
AuntMinnie
APRIL 4, 2024
A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Expert insights. Personalized for you.
52 
Let's personalize your content